UNSPSC 51112511: Mafosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5970HH9923, chemically known as ethanesulfonic acid, 2-(((2r,4r)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)-, rel- but more generally known as mafosfamide, which bears US NIH Compound Identifier 104746. European Medicines Agency schedules Mafosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG.

UNSPSC 51112511 Mafosfamide, a Commodity code, covers procurement of this alkylating chemotherapy agent by state and local health systems, correctional facilities, and specialized treatment centers. Mafosfamide is a nitrogen mustard derivative used primarily in high-dose chemotherapy protocols, often as part of conditioning regimens in hematopoietic stem cell transplantation and in treatment of certain lymphomas and solid tumors. State and local buyers under this code include state department of corrections medical services, county hospital systems, academic medical centers with oncology programs, and specialized cancer treatment facilities. The procurement typically involves unit pricing for pharmaceutical-grade mafosfamide supplied under chain-of-custody protocols, with orders governed by state pharmacy purchasing schedules, GPOs, or direct negotiation with pharmaceutical manufacturers and specialty distributors.

The source provides no recent state and local contract opportunities tagged to UNSPSC 51112511. Without posted RFPs, RFQs, IBFs, or ITBs in the recent-opportunities block, the code shows no actionable current procurement activity to assess for geographic spread or representative solicitation timing.